Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study

Fertility and Sterility

Volumn 94, Issue 4, 2010, Pages 1417-1425

  Battaglia, Cesare ^a   Mancini, Fulvia ^b   Fabbri, Raffaella ^a   Persico, Nicola ^a   Busacchi, Paolo ^a   Facchinetti, Fabio ^c   Venturoli, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

contraception; drospirenone; insulin; PCOS; Vaginal ring

Indexed keywords

C PEPTIDE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; GLUCOSE; INSULIN; NITRATE; NITRITE; TRIACYLGLYCEROL; ANDROSTANE DERIVATIVE; ETHINYLESTRADIOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOCHEMISTRY; BLOOD PRESSURE MONITORING; BRACHIAL ARTERY; CARBOHYDRATE METABOLISM; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HIRSUTISM; HOMEOSTASIS; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; LIPID METABOLISM; MENSTRUAL CYCLE; OVARY POLYCYSTIC DISEASE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VAGINA RING; VASODILATATION; BLOOD; BLOOD FLOW; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CARDIOVASCULAR FUNCTION; COMPLICATION; DRUG EFFECTS; ECHOGRAPHY; FEMALE CONTRACEPTIVE DEVICE; OVARY; PATHOPHYSIOLOGY; POLYCYSTIC OVARY SYNDROME; PROCEDURES; RISK FACTOR; VASCULARIZATION; YOUNG ADULT;

ADULT; ANDROSTENES; BLOOD PRESSURE; BRACHIAL ARTERY; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; CONTRACEPTION; CONTRACEPTIVE DEVICES, FEMALE; ETHINYL ESTRADIOL; FEMALE; HUMANS; INSULIN; OVARY; PILOT PROJECTS; POLYCYSTIC OVARY SYNDROME; REGIONAL BLOOD FLOW; RISK FACTORS; YOUNG ADULT;

EID: 77956184398     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.05.044     Document Type: Article

References (36)

1. C. Meyer, B.P. McGrath, and H.J. Teede Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease J Clin Endocrinol Metab 90 2005 5711 5716
2. R.S. Legro Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 24 2003 302 312
3. J.P. Baillargeon, D.K. McClish, P.A. Essah, and G.E. Nestler Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis J Clin Endocrinol Metab 90 2005 3863 3870
4. World Health Organization WHO collaborative study of cardiovascular disease and steroid hormone contraception. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study Lancet 349 1997 1202 1209
5. U. Gaspard, A. Scheen, J. Endrikat, C. Buicu, P. Lefebvre, C. Gerlinger, and R. Heithecker Randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism Contraception 67 2003 423 429
6. F.J.M.E. Roumen Review of the combined contraceptive vaginal ring NuvaRing® Therap and Clinic Risk Manag 4 2008 441 451
7. H.-J. Ahrendt, I. Nisand, C. Bastianelli, M.A. Gomez, C. Gemzell-Danielsson, and W. Urdl Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30μg of ethinyl estradiol and 3 mg of drospirenone Contraception 74 2006 451 457
8. S. Moncada, R.M.J. Palmer, and E.A. Higgs Nitric oxide: physiology, pathophisiology, and pharmacology Pharmacol Rev 43 1991 109 142
9. C. Battaglia, F. Mancini, A. Cianciosi, P. Busacchi, F. Facchinetti, and G. Marchesini Reggiani Vascular risk in young women with polycystic ovary and polycystic ovary syndrome Obstet Gynecol 111 2008 385 395
10. M.C. Corretti, T.J. Anderson, E.J. Benjamin, D. Celermajer, F. Charbonneau, and M.A. Creager International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery J Am Coll Cardiol 39 2002 257 265
11. C. Battaglia, P.G. Artini, G. D'Ambrogio, A.D. Genazzani, and A.R. Genazzani The role of color Doppler imaging in the diagnosis of polycystic ovary syndrome Am J Obstet Gynecol 172 1995 108 113
12. C. Battaglia, P.G. Artini, M. Salvatori, S. Giulini, F. Petraglia, and N. Maxia Ultrasonographic patterns of polycystic ovaries: color Doppler and hormonal correlations Ultrasound Obstet Gynecol 11 1998 332 336
13. D. Ferriman, and J.D. Gallwey Clinical assessment of body hair growth in women J Clin Endocrinol 21 1971 1440 1447
14. J. Zaidi, D. Jurkovic, S. Campbell, E. Okokon, and S.L. Tan Circadian variation in uterine artery blood flow indices during the follicular phase of the menstrual cycle Ultrasound Obstet Gynecol 5 1995 406 410
15. A. Ringqvist, K. Caidahl, A.S. Petersson, and A. Wennmalm Diurnal variation of flow-mediated vasodilation in healthy premenopausal women Am J Physiol Heart Circ Physiol 279 2000 H2720 H2725
16. J.A. Staessen, R. Fagard, L. Thijs, and A. Amery the Participants in the Fourth International Consensus Conference on the 24-Hour Ambulatory Blood Pressure Monitoring. A consensus view on the technique of ambulatory blood pressure monitoring Hypertension 26 1995 912 918
17. M.H. Tan, D. Johns, and B.N. Glazer Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes Clin Chem 50 2004 1184 1188
18. F. Facchinetti, S. De Martis, I. Neri, A. Caputo, and A. Volpe Effects of transdermal glyceryltrinitrate on 24-h blood pressure changes in patients with gestational hypertension Prenat Neonat Med 2 1997 22 28
19. C. Battaglia, G. Regnani, T. Marsella, F. Facchinetti, A. Volpe, and S. Venturoli Adjuvant L-arginine treatment in controlled ovarian hyperstimulation: a double-blind, randomized study Hum Reprod 17 2002 659 665
20. M. Modan, M.I. Harris, and H. Halkin Evaluation of WHO and NDDG criteria for impaired glucose tolerance. Results from two national samples Diabetes 38 1989 1630 1635
21. P. Muhn, R. Krattenmacher, S. Beier, W. Elger, and E. Schillinger Drospirenone: a novel progestogen with antimineralcorticoid and antiandrogenic activity: pharmacological characterization in animal models Contraception 51 1995 99 110
22. C. Battaglia, A.D. Genazzani, P.G. Artini, M. Salvatori, S. Giulini, and A. Volpe Ultrasonographic and color Doppler analysis in the treatment of polycystic ovary syndrome Ultrasound Obstet Gynecol 12 1998 180 187
23. M. Guido, D. Romualdi, M. Giuliani, S. Suriano, L. Selvaggi, and R. Apa Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study J Clin Endocrinol Metab 89 2004 2817 2823
24. E. Diamanti-Kandarakis, J.P. Baillargeon, M.J. Iuorno, D.J. Jakubowicz, and J.E. Nestler A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pill J Clin Endocrinol Metab 88 2003 1927 1932
25. I.F. Godsland, D. Crook, R. Simpson, T. Proudler, C. Felton, and B. Lees The effects of different formulations of oral contraceptive agents on lipid and carbohydratemetabolism N Engl JMed 323 1990 1375 1381
26. M. Palep-Singh, K. Mook, J. Barth, and A. Balen An observational study of Yasmin ® in the management of women with polycystic ovary syndrome J Fam Plan Reprod Health Care 30 2004 163 165
27. M.A. Abdul-Ghani, C.P. Jenkinson, D.K. Richardson, D. Tripathy, and R.A. DeFronzo Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study Diabetes 55 2006 1430 1435
28. R. Pasquali, A. Gambineri, B. Anconetani, V. Vicennati, D. Colitta, and E. Caramelli The natural history of the metabolic syndrome in young women with polycystic ovary syndrome and the effect of long-term oestrogen-progestogen treatment Clin Endocrinol 50 1999 517 527
29. D. Cibula, M. Fanta, J. Vrbikova, S. Stanicka, K. Dvorahova, and M. Hill The effect of combination therapy with metformin and combined oral contraceptive (COC) versus COC alone on insulin sensitivity, hyperandrogenemia, SHBG, and lipids in PCOS patients Hum Reprod 20 2005 180 184
30. A. Cagnacci, A.M. Paoletti, A. Renzi, M. Orru, M. Pilloni, and G.B. Melis Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptive containing cyproterone acetate or desogestrel J Clin Endocrinol Metab 88 2003 3621 3625
31. S. Nader, M.G. Riad-Gabriel, and M.F. Saad The effect of desogestrel-containing oral contraceptives on glucose tolerance and leptin concentrations in hyperandrogenic women J Clin Endocrinol Metab 82 1997 3074 3077
32. C. Charitidou, D. Farmakiotis, V. Zournatzi, I. Pidonia, T. Pegiou, and N. Karamanis The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome Atherosclerosis 196 2008 958 965
33. W.H.K. Oelkers Drospirenone in combination with estrogens: for contraception and hormone replacement therapy Climacteric 8 2005 19 27
34. E.A. Anderson, and A.L. Mark Flow-mediated and reflex changes in large peripheral artery tone in humans Circulation 79 1989 93 100
35. B. Gerasimovska-Kitanovska, K. Zafirovska, S. Bogdanovska, L. Lozance, and G. Severova-Andreevska Decreased nitric oxide in women with essential hypertension in prehypertensive phase Croat Med J 46 2005 889 893
36. S.R. Kashyap, L.J. Roman, J. Lamont, B.S. Masters, M. Bajaj, and S. Suraamornkul Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects J Clin Endocrinol Metab 90 2005 1100 1105